China’s Walvax Raises $72.8 Million in Private Placement

Walvax Biotechnology, headquartered in China’s Yunnan Province, raised $72.8 million in a private placement. Walvax is known as a vaccine company, with vaccines for both meningococcal disease and flu, though it ventured into monoclonal antibodies by acquiring a majority stake in Genor Pharma in December 2013. The company said it would use $51 million of its new capital to pay off existing loans. More details.... Stock Symbol:(SHE: 300142) Share this with colleagues: // //